ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase inhibitors are commonly employed for an oncogene-driven subset of NSCLC patients, targeting ALK rearrangement specifically, which produces in turn leads to generation of the ALK protein before causing tumor cells to grow and spread (Straughan D et al., 2016).